Protagenic Therapeutics, Inc.
21.3.2024 13:43:15 CET | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten consecutive trading days. This resolves the issue of potential delisting from Nasdaq by May 19, 2024 that the company had been facing.
On Tuesday, November 21, 2023, the company received a deficiency letter from Nasdaq stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, because it had not maintained a minimum bid price of $1.00 per share for 30 consecutive trading days. The Notification Letter stated that the company had 180 calendar days, or until May 19, 2024, to regain compliance by having a closing bid price of at least $1.00 per share for ten consecutive trading days. On March 19, 2024, the company received a formal notice from Nasdaq confirming that it has regained compliance with Listing Rule 5550(a)(2).
About Protagenic Therapeutics, Inc.:
Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is committed to pioneering neuro-active peptides into therapeutics to mitigate stress-related disorders. For more information, visit www.protagenic.com.
About PT00114:
PT00114, a 41-amino-acid synthetic peptide, holds promise in treating various neuro-psychiatric conditions, including depression, anxiety, and PTSD. It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels.
Forward-Looking Statements:
This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements.
Company Contact:
Alexander K. Arrow, MD, CFA Chief Financial Officer Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010. Tel: 213-260-4342 Email: alex.arrow@protagenic.com
Investor Relations Contact:
Kirin M. Smith, President, PCG Advisory, Inc. 950 Third Avenue, Suite #2700, New York, NY 10022. Tel: 646-823-8656 Email: ksmith@pcgadvisory.com
SOURCE: Protagenic Therapeutics, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
ePropelled to Showcase Next Generation Electric Propulsion, Software Innovation and Autonomous Systems Capabilities at Farnborough International Airshow 202617.7.2026 17:00:00 CEST | Press release
Meet the ePropelled team in Hall 2, Stand 2039, on the New Hampshire Mission Pavilion FARNBOROUGH, UK / ACCESS Newswire / July 17, 2026 / ePropelled, a leading global provider of smart propulsion solutions and energy management systems, will exhibit at the Farnborough International Airshow 2026, showcasing its latest innovations for aerospace, defense and uncrewed vehicle applications. Visitors to Hall 2, Stand 2039 on the New Hampshire Mission Pavilion will have the opportunity to meet the ePropelled team and learn about a range of exciting developments, including new product launches, software innovations, technology updates and exclusive previews of next-generation solutions currently in development. With autonomy, electrification and intelligent mobility driving the future of aerospace and defence, ePropelled continues to develop advanced propulsion, power management and software technologies that enhance performance, efficiency and mission capability across air, land and maritime
As the UK Backs Life Sciences and Advanced Manufacturing, US PMO Firm MustardSeed Moves In to Help Deliver It16.7.2026 11:00:00 CEST | Press release
The expansion reflects growing client demand for embedded programme management support across highly regulated industries. WEST CHESTER, PA AND MANCHESTER, UK / ACCESS Newswire / July 16, 2026 / The UK Government's 2025 Modern Industrial Strategy has put life sciences, advanced manufacturing, defence, and clean energy at the centre of Britain's growth agenda. MustardSeed, a US-based programme management and PMO consultancy, is launching UK operations to help organisations in those sectors deliver on that ambition. The 2025 Modern Industrial Strategy names life sciences and advanced manufacturing among its eight priority sectors, alongside defence and clean energy. These are industries defined by complex, regulated, multi-stakeholder programmes where disciplined execution directly determines commercial and operational outcomes. MustardSeed, headquartered in West Chester, Pennsylvania, has built its practice around delivering that execution. The firm announced today the launch of its UK
Akkodis Recognized in the 2026 Gartner(R) Emerging Market Quadrant for Physical AI Services16.7.2026 06:45:00 CEST | Press release
Akkodis continues to advance full-stack engineering expertise and industrial-grade AI deployments. ZURICH, SWITZERLAND / ACCESS Newswire / July 16, 2026 / Akkodis, a global digital engineering consulting company and part of the Adecco Group, has been recognized as a Specialist in the Gartner Emerging Market Quadrant for Physical AI Services (PAIS), published on June 8, 2026. Physical AI services address the complex challenge of designing, developing, deploying and operating AI‑enabled physical systems - such as robots, autonomous systems including, vehicles, drones and industrial infrastructure - in real‑world environments. The Gartner report states "The PAIS market is moving from exploratory experimentation toward operational reliability at scale. This trend is driven by mounting labor constraints, safety requirements, infrastructure modernization and advances in AI, simulation and automation technologies." Full‑stack Physical AI capabilities with real‑world impact and measurable outc
Loar Holdings Inc. Announces Date and Time for Second Quarter 2026 Earnings and Conference Call15.7.2026 22:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / July 15, 2026 / Loar Holdings Inc. (NYSE:LOAR) will report Q2 2026 earnings before the market opens on Thursday, August 6, 2026. A conference call will follow at 11:00a.m. Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website: https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations IR@loargro
Fermi Outlines Strategic Rationale for Upsized $431 Million Convertible Notes Offering15.7.2026 14:30:00 CEST | Press release
Flexible convertible structure with shareholder-friendly capped call minimizes dilution Proceeds strengthen liquidity in midst of customer and partner negotiations and preserve Fermi's speed-to-power advantage Attractive five-year cost of capital provides run room to advance multiple commercial tracks in parallel DALLAS, TX / ACCESS Newswire / July 15, 2026 / Fermi Inc. (Nasdaq:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), outlined today the strategic rationale for its recently closed and upsized offering of $431.25 million aggregate principal amount of 5.00% Convertible Senior Notes due 2031 (the "Notes"), which included the exercise in full of the initial purchasers' 13-day option to purchase up to an additional $56.25 million aggregate principal amount of Notes. The Notes are intended to strengthen Fermi's balance sheet, enhance liquidity, and support continued execution of Project Matador as the Company advances tenant, strategic partnership, and power-de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom